These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 9659960)
1. Government investigates ongoing shortage of i.v. immune globulin. Am J Health Syst Pharm; 1998 Jul; 55(13):1341-2, 1344. PubMed ID: 9659960 [No Abstract] [Full Text] [Related]
2. Availability of immune globulin intravenous for treatment of immune deficient patients--United States, 1997-1998. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 1999 Mar; 48(8):159-62. PubMed ID: 10079062 [TBL] [Abstract][Full Text] [Related]
3. Immune globulin and the shortage of plasma derivatives. Tecnologica; 1999 Feb; ():1, 3-8, 10. PubMed ID: 10848145 [No Abstract] [Full Text] [Related]
4. Intravenous immune globulin removed from world market. Infect Control Hosp Epidemiol; 1994 May; 15(5):356-7. PubMed ID: 8077652 [No Abstract] [Full Text] [Related]
5. Does Canada face a crisis? US considers ending plasma exports. Sibbald B CMAJ; 1998 Jun; 158(12):1639-41. PubMed ID: 9645181 [TBL] [Abstract][Full Text] [Related]
6. Possible incompatibilities with immune globulin for i.v. use. Hazlet TK; Tankersley DL Am J Hosp Pharm; 1993 Apr; 50(4):654, 659-60. PubMed ID: 8470675 [No Abstract] [Full Text] [Related]
7. Changes in IVIG marketplace challenge pharmacists. Thompson CA Am J Health Syst Pharm; 2005 Nov; 62(22):2329-30, 2332. PubMed ID: 16278315 [No Abstract] [Full Text] [Related]
8. The FDA and the pharmaceutical industry: is regulation contributing to drug shortage? Roman A Albany Law Rev; 2013-2014; 77(2):539-77. PubMed ID: 24851322 [No Abstract] [Full Text] [Related]
17. Respiratory syncytial virus immune globulin intravenous (human) receives marketing approval in Canada. Langley JM Can Fam Physician; 1998 Jan; 44():113. PubMed ID: 9481469 [No Abstract] [Full Text] [Related]
18. Drug Price Gouging: When Will it End? Siwek J Am Fam Physician; 2017 Jul; 96(1):20. PubMed ID: 28671372 [No Abstract] [Full Text] [Related]
19. A precarious balancing act--the role of the FDA as protector of public health and industry wealth. McCabe AR Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844 [No Abstract] [Full Text] [Related]
20. Who pays what in drug development. Love J Nature; 1999 Jan; 397(6716):202. PubMed ID: 9930689 [No Abstract] [Full Text] [Related] [Next] [New Search]